RxDoctor Payments Data

Hind Kettani, MD

Neurology · Tampa, FLNPI 1982832952

Payments from drug & device makers

$129,039in general payments, 2019–2025

Across 1,160 payments — averaging $111.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$43K
  • UCB, Inc.$37K
  • SK Life Science, Inc.$19K
  • Livanova USA, Inc.$9K
  • Catalyst Pharmaceuticals, Inc.$6K
  • AbbVie$3K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$11,1689%
  • Speaking & faculty fees$76,67759%
  • Travel & lodging$9,5077%
  • Food & beverage$31,63225%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.86$42,590
UCB, Inc.212$37,053
SK Life Science, Inc.87$19,210
Livanova USA, Inc.41$8,971
Catalyst Pharmaceuticals, Inc.13$5,774
AbbVie(2 entities)150$2,737
Eisai Inc.29$720
Pfizer34$571
Teva Pharmaceuticals USA, Inc.20$552
Greenwich Biosciences, Inc.11$541
Biogen24$501
Amgen(2 entities)27$500
Lilly USA, LLC27$470
Novartis17$454
Sunovion Pharmaceuticals Inc.19$445
Sanofi11$400
Acadia Pharmaceuticals Inc23$390
Biohaven Pharmaceuticals, Inc.20$389
Biohaven Pharmaceutical Holding Company Ltd.23$386
Zyla Life Sciences, Inc.47$385
Neurelis, Inc.8$369
Sumitomo Pharma America, Inc.18$340
Harmony Biosciences LLC12$331
Neurocrine Biosciences, Inc.12$327
Takeda Pharmaceuticals U.S.A., Inc.11$306
Neuropace, Inc.2$303
AstraZeneca(2 entities)9$271
Avanir Pharmaceuticals, Inc.10$265
MDD US Operations, LLC14$250
EMD Serono, Inc.11$216
Lundbeck LLC8$210
Tanabe Pharma America, Inc.7$206
Immedica Pharma US, Inc.2$194
Supernus Pharmaceuticals, Inc.11$176
Azurity Pharmaceuticals, Inc.7$149
CSL Behring7$137
Acorda Therapeutics, Inc6$131
Bristol Myers Squibb6$131
Arbor Pharmaceuticals, Inc.7$123
Gilead1$121
Argenx US, Inc.4$118
Axsome Therapeutics, Inc.4$101
Amneal Pharmaceuticals LLC5$98
Aquestive Therapeutics, Inc.6$96
Merz North America, Inc.4$94
Upsher-smith Laboratories LLC6$83
Almatica Pharma LLC4$82
Cala Health, Inc.4$77
Alnylam Pharmaceuticals Inc.3$59
Johnson & Johnson(2 entities)2$57
Bausch Health US, LLC3$57
Kyowa Kirin, Inc.3$55
Mallinckrodt Hospital Products Inc.2$50
Banner Life Sciences, LLC2$49
GE HealthCare2$44
Impel Pharmaceuticals Inc.1$36
Promius Pharma LLC2$36
Aucta Pharmaceuticals, Inc.2$30
Impel Pharmaceuticals LLC1$25
Chiesi USA, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,039 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$47,194
Medicare patients
251
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam93$154,788
UbrelvyUbrogepant63$111,555
Nurtec OdtRimegepant Sulfate41$80,790
XcopriCenobamate65$80,254
AptiomEslicarbazepine Acetate36$77,175
QuliptaAtogepant26$44,004
Lamictal XrLamotrigine12$39,771
BotoxOnabotulinumtoxina22$29,356
NayzilamMidazolam25$23,752
Emgality PenGalcanezumab-Gnlm13$23,122
Aimovig AutoinjectorErenumab-Aooe18$17,031
FycompaPerampanel12$16,072
Lamotrigine ErLamotrigine18$13,239
Tegretol XrCarbamazepine22$12,612
Rivastigmine24$8,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$2,737$184,914111 claims
UCB, Inc.Briviact, Nayzilam$37,053$178,540118 claims
PfizerNurtec Odt, Dilantin$571$83,91052 claims
SK Life Science, Inc.Xcopri$19,210$80,25465 claims
Sunovion Pharmaceuticals Inc.Aptiom$445$77,17536 claims
Eisai Inc.Fycompa$720$16,07212 claims
Upsher-smith Laboratories LLCTopiramate$83$2,318100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →